Evidence map›Paper›PMID 34214473›Full record

ArticleCancer cell2021

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.

Alfredo Addeo, Pankil K Shah, Natacha Bordry, Robert D Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, Pierre-Yves Dietrich, Barbara S Taylor, Pierre-Francois Simand and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Alfredo AddeoDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland. Electronic address: alfredo.addeo@hcuge.ch.
Pankil K ShahMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Natacha BordryDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Robert D HudsonMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Brenna AlbrachtMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Mariagrazia Di MarcoDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Virginia KaklamaniMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Pierre-Yves DietrichDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Barbara S TaylorDivision of Infectious Diseases, Department of Medicine, Joe R. and Teresa Lozano Long School of Medicine, UT Health San Antonio, San Antonio, TX, USA.
Pierre-Francois SimandDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Darpan PatelMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Jing WangMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Intidhar Labidi-GalyDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland; Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.
Sara FertaniDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Robin J LeachMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Jose SandovalDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Ruben MesaMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Kate LathropMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
Nicolas MachDepartment of Oncology, Geneva University Hospitals, University of Geneva, Swiss Cancer Center Leman, Switzerland.
Dimpy P ShahMays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA. Electronic address: shahdp@uthscsa.edu.

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
NCI NIH HHS P30 CA054174
6 · The paper itself

Abstract

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.

Indexed as

AgedCOVID-19COVID-19 VaccinesFemaleHost-Pathogen InteractionsHumansImmunityMaleMiddle AgedmRNA VaccinesNeoplasmsSARS-CoV-2SeroconversionVaccines, SyntheticCOVID-19 VaccinesmRNA VaccinesVaccines, Syntheticantibodyanti-cancer treatmentCOVID-19immune responsemalignancyoncologypandemicseroconversiontumorvaccine

Identifiers

PMID34214473
PMCPMC8218532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.